Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 4Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3NETWORK 3

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 4Lymphoid 1CNS 1

Conditions

Breast Neoplasms 545Lymphoma 444Precursor Cell Lymphoblastic Leukemia-Lymphoma 409Lymphoma, Large B-Cell, Diffuse 347Leukemia 344Multiple Myeloma 335Lymphoma, Non-Hodgkin 316Leukemia, Myeloid, Acute 288Leukemia, Lymphocytic, Chronic, B-Cell 285Lymphoma, Follicular 240Burkitt Lymphoma 217Myelodysplastic Syndromes 209Lymphoma, Mantle-Cell 201Hodgkin Disease 193Recurrence 151Lymphoma, B-Cell, Marginal Zone 142Melanoma 134Lymphoma, Large-Cell, Immunoblastic 116Neoplasms 109Lymphoma, B-Cell 103Neuroblastoma 101Neoplasms, Plasma Cell 99Ovarian Neoplasms 94Triple Negative Breast Neoplasms 93Leukemia, Myelogenous, Chronic, BCR-ABL Positive 91Myeloproliferative Disorders 87Hematologic Neoplasms 87Leukemia, Myeloid, Chronic-Phase 83Leukemia, Myeloid, Accelerated Phase 80Leukemia, Myelomonocytic, Chronic 78

Interventions

Magnetic Resonance Spectroscopy 6Dexamethasone 6Cyclophosphamide 6Blood Specimen Collection 6Prednisone 5Positron Emission Tomography Computed Tomography 4Mammography 4Lenalidomide 4Colonoscopy 4pembrolizumab 3Tomography, X-Ray Computed 3Surveys and Questionnaires 3Melphalan 3Exercise 3Biopsy 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3weifuchun 2obinutuzumab 2fluciclovine F-18 2daratumumab 2carfilzomib 2Preoperative Exercise 2Positron-Emission Tomography 2Methods 2Magnetic Resonance Imaging 2Injections 2Gemcitabine 2Educational Status 2Doxorubicin 2Cytarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Disease × Cyclophosphamide × Clear all
NCT03152318 2026-03-04

rQNestin

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
62 enrolled
CNS

Astrocytoma, Brain Neoplasms, Disease, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma

NCT01857115 2024-11-13

wCCyd

European Myeloma Network B.V.

Phase 1/2 Completed
63 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT01093196 2024-11-07

Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

Fondazione EMN Italy Onlus

Phase 3 Completed
660 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT01190787 2024-01-23

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

European Myeloma Network B.V.

Phase 2 Completed
150 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT02204241 2023-07-03

CCD

European Myeloma Network B.V.

Phase 1/2 Completed
36 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT01659099 2018-03-07

GAINED

The Lymphoma Academic Research Organisation

Phase 3 Terminated
671 enrolled
Lymphoid

Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡